Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say?

M Amin, DJ No, A Egeberg, JJ Wu - American Journal of Clinical …, 2018 - Springer
An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …
被引用次数：81 相关文章

Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?

M Amin, DJ No, A Egeberg… - American journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …

Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?

M Amin, DJ No, A Egeberg… - American Journal of …, 2018 - research.regionh.dk
An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …

Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?

M Amin, DJ No, A Egeberg, JJ Wu - American Journal of Clinical …, 2018 - europepmc.org
An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …